{"id":234518,"date":"2026-09-08T12:09:32","date_gmt":"2026-09-08T06:39:32","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=234518"},"modified":"2026-09-08T12:09:33","modified_gmt":"2026-09-08T06:39:33","slug":"is-amrutanjan-health-care-a-good-buy-after-q1-fy27-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/is-amrutanjan-health-care-a-good-buy-after-q1-fy27-results\/","title":{"rendered":"Is Amrutanjan Health Care a Good Buy After Its Q1 FY27 Results?"},"content":{"rendered":"

Amrutanjan Health Care share price around Rs 496. 37.3% below 52-week high of Rs 791. Q1 FY27 revenue Rs 103 crore, up 9.5% YoY. PAT Rs 4.37 crore, down 47.4%. PE 27x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Amrutanjan Health Care’s Q1 FY27 results were mixed, with revenue at Rs 103 crore but PAT falling 47% to Rs 4.37 crore. The Amrutanjan Health Care share price near Rs 496 has not escaped this pressure, and the profit decline is the key data point investors should weigh before deciding whether Amrutanjan Health Care is a good buy right now.<\/p>\n<\/div>\n

The Amrutanjan Health Care share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Amrutanjan Health Care is a consumer healthcare company known for pain-relief balms, expanding into women’s hygiene products, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.<\/p>\n

Revenue for the quarter came in at Rs 103 crore, up 9.5% year on year, while profit after tax came in at Rs 4.37 crore, down 47.4% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Amrutanjan Health Care share price from here.<\/p>\n

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Amrutanjan Health Care share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n